To piggyback off of Morgan's question about treatment duration, a question about treatment initiation:
In these trials mepolizumab was used as an adjunctive therapy for patients with COPD exacerbations already on triple inhaled therapy. Might there be a role for using anti-IL5 therapy earlier in the treatment course for patients with COPD and an eosinophilic phenotype?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.